Evidence map›Paper›PMID 39248600›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2024

Orientation Regulation of Class-switch Recombination in Human B Cells.

Likun Du, Valentyn Oksenych, Hui Wan, Xiaofei Ye, Junchao Dong, Adam Yongxin Ye, Hassan Abolhassani, Stelios Vlachiotis, Xuefei Zhang, Kathrin de la Rosa and 4 more

Abstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Likun DuDivision of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-8448-2187
Valentyn OksenychDivision of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
Hui WanDivision of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
Xiaofei YeDivision of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
Junchao DongDepartment of Immunology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China.
Adam Yongxin YeDepartment of Genetics, Harvard Medical School, Boston, MA.
Hassan AbolhassaniDivision of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-4838-0407
Stelios VlachiotisDivision of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
Xuefei ZhangDepartment of Genetics, Harvard Medical School, Boston, MA.
Kathrin de la RosaDepartment of Cancer and Immunology, Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.ORCID 0000-0003-4809-3157
Lennart HammarströmDivision of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
Mirjam van der BurgDepartment of Pediatrics, Laboratory for Pediatric Immunology, Leiden University Medical Center, Leiden, the Netherlands.
Frederick W AltDepartment of Genetics, Harvard Medical School, Boston, MA.
Qiang Pan-HammarströmDivision of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0003-1990-8804

Funding

Cancerfonden (Swedish Cancer Society)KI | Center for Innovative Medicine (CIMED)Knut och Alice Wallenbergs Stiftelse (Knut and Alice Wallenberg Foundation)Kreftforeningen (NCS) 182355Norges Forskningsråd (Forskningsrådet) 291217Norges Forskningsråd (Forskningsrådet) 291217Vetenskapsrådet (VR)Vetenskapsrådet (VR)
6 · The paper itself

Abstract

We developed a linear amplification-mediated high-throughput genome-wide translocation sequencing method to profile Ig class-switch recombination (CSR) in human B cells in an unbiased and quantitative manner. This enables us to characterize CSR junctions resulting from either deletional recombination or inversion for each Ig class/subclass. Our data showed that more than 90% of CSR junctions detected in peripheral blood in healthy control subjects were due to deletional recombination. We further identified two major CSR junction signatures/patterns in human B cells. Signature 1 consists of recombination junctions resulting from both IgG and IgA switching, with a dominance of Sµ-Sγ junctions (72%) and deletional recombination (87%). Signature 2 is contributed mainly by Sµ-Sα junctions (96%), and these junctions were almost all due to deletional recombination (99%) and were characterized by longer microhomologies. CSR junctions identified in healthy individuals can be assigned to both signatures but with a dominance of signature 1, whereas almost all CSR junctions found in patients with defects in DNA-PKcs or Artemis, two classical nonhomologous end joining (c-NHEJ) factors, align with signature 2. Thus, signature 1 may represent c-NHEJ activity during CSR, whereas signature 2 is associated with microhomology-mediated alternative end joining in the absence of the studied c-NHEJ factors. Our findings suggest that in human B cells, the efficiency of the c-NHEJ machinery and the features of switch regions are crucial for the regulation of CSR orientation. Finally, our high-throughput method can also be applied to study the mechanism of rare types of recombination, such as switching to IgD and locus suicide switching.

Indexed as

B-LymphocytesImmunoglobulin Class SwitchingRecombination, GeneticDNA End-Joining RepairHigh-Throughput Nucleotide SequencingHumans

Identifiers

PMID39248600
PMCPMC11457721

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.